Novo Nordisk has advised that the Therapeutic Goods Administration (TGA) has removed Ozempic^® (semaglutide) from its medicines shortage list effective 18 July 2025. Ozempic^® is indicated for the treatment of type 2 diabetes.

Over the last two years, we have made substantial investments to expand our global manufacturing capacity and stabilise supply. We are now seeing the results of these efforts, with supply levels restored. This allows for new Ozempic^® patient initiations and supporting continuity of care for patients already on the treatment.

For the latest prescribing guidance and information, please refer to the TGA website.

Novo Nordisk has advised the TGA about the planned phase out of Novo Nordisk insulin products, which will occur over the next two years and will focus on older generation products with multiple presentations. This is part of a global insulin portfolio consolidation strategy and is not a result of any safety, efficacy or quality-related concerns.

The table below lists the products and presentations that will be impacted in Australia.

We remain committed to working closely with health authorities, the medical community, and patient advocacy groups, in accordance with local regulations, to ensure that patients have access to the medications they need.

We will provide support materials to healthcare professionals to assist patients transitioning to alternative treatments closer to the timings of each product phase out.